Swedish Orphan Biovitrum AB (publ) (FRA:B6E)

Market Cap	13.03B +30.1%
Revenue (ttm)	2.61B +8.5%
Net Income	44.17M -87.7%
EPS	0.13 -87.8%
Shares Out	n/a
PE Ratio	294.92
Forward PE	20.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	40
Open	37.72
Previous Close	39.08
Day's Range	37.72 - 37.72
52-Week Range	22.40 - 39.08
Beta	n/a
RSI	63.76
Earnings Date	Feb 5, 2026

About FRA:B6E

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1939
• Employees: 1,888
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: B6E

Financial Performance

In 2025, FRA:B6E's revenue was 28.24 billion, an increase of 8.50% compared to the previous year's 26.03 billion. Earnings were 478.00 million, a decrease of -87.70%.

Financial numbers in SEK